Your email has been successfully added to our mailing list.

×
0.00107642626480103 0.00107642626480103 0.00588805166846076 0.00588805166846076 -0.00538213132400419 -0.00699677072120554 -0.00645855758880503 -0.00645855758880503
Stock impact report

Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018

Athenex, Inc. (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
Company Research Source: GlobeNewswire
BUFFALO, N.Y., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that an abstract for the data from the Phase II study of KX2-391 in 168 patients with actinic keratosis has been accepted for oral presentation and online ePoster at the American Academy of Dermatology Annual Meeting in San Diego on February 17, 2018. The abstract is entitled “Phase II Study of KX2-391 Ointment 1%, a Novel Field Treatment Based on Src/Tubulin Polymerization Inhibition, for Actinic Keratosis”. KX2-391, also known as KX-01, is a novel dual Src kinase and tubulin polymerization inhibitor that Athenex is developing into a topical formulation for the treatment of actinic keratosis. Actinic keratosis is a common skin condition in fair-skinned people that is induced through ultra-violet light damage, resulting in p Show less Read more
Impact Snapshot
Event Time:
ATNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ATNX alerts
Opt-in for
ATNX alerts

from News Quantified
Opt-in for
ATNX alerts

from News Quantified